Asceneuron SA has appointed Peter Van Vlasselaer as chair of its board of directors to help guide development of the company’s treatments for neurodegenerative diseases. Dr Van Vlasselaer was most recently the founder and chief executive of Armo Biosciences Inc, an oncology company acquired by Eli Lilly and Co in 2018. He also helped found InterMune, now part of Roche.
Dr Van Vlasselaer has a degree in zoology and a PhD in immunology from the Catholic University of Leuven in Belgium. He also did post-doctoral work in the Division of Immunology and Rheumatology at the Stanford University Medical School, US.
Asceneuron announced the appointment on 17 January 2019.
Copyright 2019 Evernow Publishing Ltd.